Regadenoson anhydrous
As of the edition of 20 October 2026, Regadenoson anhydrous is a small molecule: marketed, first approved in 2008 (US); acts on ADORA2A; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Lexiscan
- First approved
- 10 April 2008 (US)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- GE Healthcare; 3 holders in all
- Registered trials
- 53, 6 stopped early
- Disease areas
- Heart and blood vessels; Blood and lymph; Inherited and neonatal; Lungs and airways; Cancer; Eye
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Astellas.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Regadenoson anhydrous.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADORA2A | Adenosine receptor A2a | P29274 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 15 | 13 | 0 | 2 |
| Phase 1 | 11 | 8 | 1 | 1 |
| Phase 2 | 11 | 5 | 2 | 3 |
| Phase 3 | 5 | 5 | 0 | 0 |
| Phase 4 | 11 | 9 | 1 | 0 |
| All trials | 53 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Astellas | Originator and Lead sponsor of trials | 2008 to now |
| GE Healthcare | Applicant | 2010 to now |
| GE Healthcare | Applicant and Lead sponsor of trials | 2017 to now |